Skip to main content
SpringerLink
Log in

Effect of Ketanserin on Lipoproteins in Patients with Essential Hypertension

  • Short Communication
  • Poster Presentations: Clinical Pharmacology
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Allain CC, Poon LS, Chan CS, et al. Enzymatic determination of total serum cholesterol. Clinical Chemistry 20: 470–475, 1979

    Google Scholar 

  • Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochimica et Biophysica Acta 665: 408–419, 1981

    Article  PubMed  CAS  Google Scholar 

  • Eggstein M, Kreutz FH. Eine neue Bestimmung der Neutralfette im Blutserum and Gewebe. I. Mitt. Prinzip. Durchfuhrung and Besprechung des Methode. Klinische Wochenschrift 44: 262, 1966

    Article  PubMed  CAS  Google Scholar 

  • Eisenberg S. High density lipoprotein metabolism. Journal of Lipid Research 25: 1017–1058, 1984

    PubMed  CAS  Google Scholar 

  • Ferrara LA, Fasano ML, Soro S. Metabolic aspects of antihypertensive treatment with ketanserin. Journal of Cardiovascular Pharmacology 7: 1007–1008, 1985

    Article  PubMed  CAS  Google Scholar 

  • Goto Y, Akanuma Y, Harano Y, et al. Determination by the SRID method of normal values of serum apolipoproteins (A-I, A-II, B, C-H, C-III and E) in normolipidemic healthy Japanese subjects. Journal of Clinical Biochemistry and Nutrition 1: 73–88, 1986

    Article  CAS  Google Scholar 

  • Havel RJ, Edger HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. Journal of Clinical Investigation 34: 1345–1353, 1955

    Article  PubMed  CAS  Google Scholar 

  • Hedner T, Persson B, Bergland G. Ketanserin, a novel 5-hydroxytryptamine antagonist; monotherapy in essential hypertension. British Journal of Clinical Pharmacology 16: 121–125, 1983

    Article  PubMed  CAS  Google Scholar 

  • Leyson JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, et al. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sciences 28: 1015–1022, 1981

    Article  Google Scholar 

  • Lijnen P, Fagard R, Staessen J, Blaton V, Hollez P, et al. Serum cholesterol during ketanserin and propranolol administration in hypertensive patients. Journal of Cardiovascular Pharmacology 10: 647–650, 1987

    Article  PubMed  CAS  Google Scholar 

  • Omvik P, Lund-Johansen P. Long-term effects on central hemodynamics and body fluid volumes of ketanserin in essential hypertension; studies at rest and during dynamic exercise. Journal of Hypertension 1: 405–412, 1983

    Article  PubMed  CAS  Google Scholar 

  • Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. Journal of the American Medical Association 213: 1143–1152, 1970

    Article  Google Scholar 

  • Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein. Journal of Lipid Research 19: 65–76, 1978

    PubMed  CAS  Google Scholar 

  • Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatment and serum lipoproteins (editorial review). Journal of Hypertension 3: 297–306, 1985

    Article  PubMed  CAS  Google Scholar 

  • Wenting GJ, Man in’t Veld AJ, Woittiez AJ, Boomsma F, Schalekamp MADH. Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist. British Medical Journal 284: 537–539, 1982

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Fukuoka University Hospital, 7-45-1 Jonan-ku, Nanakuma, Fukuoka, 814, Japan

    K. Arakawa,  Jun Sasaki, K. Saku & S. Ideishi

  2. Nakabaru Hospital, Fukuoka, Japan

    Y. Saeki

  3. Fukuoka National Central Hospital, Fukuoka, Japan

    K. Baba

  4. Wakasugi Hospital, Fukuoka, Japan

    K. Ikeda

  5. Hakujuji Hospital, Fukuoka, Japan

    Y. Kato

  6. Iizuka Hospital, Fukuoka, Japan

    H. Ohba

  7. Saiseikai Fukuoka General Hospital, Fukuoka, Japan

    H. Doi

Authors
  1. K. Arakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Saku
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Ideishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. Saeki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K. Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. Ohba
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H. Doi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arakawa, K., Sasaki, J., Saku, K. et al. Effect of Ketanserin on Lipoproteins in Patients with Essential Hypertension. Drugs 36 (Suppl 1), 126–129 (1988). https://doi.org/10.2165/00003495-198800361-00025

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198800361-00025

Keywords

Search

Navigation